AltaRex Corp - News Release
AltaRex highlights additional BrevaRex phase I data
AltaRex Corp AXO
Shares issued 62,058,898 2000-10-23 close $0.69
Tuesday Oct 24 2000 News Release
Mr. Richard Bagley reports
AltaRex has received new and preliminary data from a completed phase I clinical trial of its BrevaRex MAb demonstrating activation of cellular (T cell) immune responses in addition to the previously reported humoral (B cell) immune responses. AltaRex expects to report final results at the upcoming American Society of Hematology (ASH) annual meeting in December.
"Generation of a cellular immune response with BrevaRex MAb supports the company's understanding of the way in which its monoclonal antibodies (MAbs) work and how effective these MAbs may be as immunotherapeutics in fighting targeted cancers," commented Richard Bagley, president and chief executive officer of AltaRex. "The BrevaRex data are consistent with our studies of OvaRex MAb, our lead, late-stage product for ovarian cancer."
The company believes there are several important implications from the BrevaRex data:
The simultaneous activation of both arms of the immune system following administration of BrevaRex could generate proportionally stronger cancer-killing activity than either arm acting separately.
The consistency of mechanism findings, both preclinically among OvaRex, BrevaRex and ProstaRex MAbs, and clinically among OvaRex and BrevaRex MAbs, indicate the potential breadth of the company's pipeline for cancer treatment.
This consistency, both scientifically and medically, supports the company's belief that its proprietary technology platform represents a strong base on which additional antibody-based programs in other disease areas can eventually be developed.
BrevaRex MAb is the company's second antibody product to be tested in clinical trials. Like OvaRex MAb, it targets a circulating tumour-associated antigen. The target for BrevaRex MAb is MUC1, a tumour marker associated with most cases of multiple myeloma and also other malignancies such as breast, lung and ovarian cancers. The company is researching how to mobilize the human immune response to best help patients to fight their own disease. Subject to the availability of additional financial resources, the company intends to pursue with BrevaRex MAb, an orphan drug/fast-track development approach for the indication of multiple myeloma, a devastating cancer of the bone marrow with limited treatment options.
WARNING: The company relies upon litigation protection for "forward-looking" statements.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com
old url (better for printing) |
